Literature DB >> 11238622

Critical requirement for the membrane-proximal cytosolic tyrosine residue for CD28-mediated costimulation in vivo.

Y Harada1, M Tokushima, Y Matsumoto, S Ogawa, M Otsuka, K Hayashi, B D Weiss, C H June, R Abe.   

Abstract

The YMNM motif that exists in the CD28 cytoplasmic domain is known as a binding site for phosphatidylinositol 3-kinase and Grb-2 and is considered to be important for CD28-mediated costimulation. To address the role of the YMNM motif in CD28 cosignaling in primary T cells, we generated transgenic mice on a CD28 null background that express a CD28 mutant lacking binding ability to phosphatidylinositol 3-kinase and Grb-2. After anti-CD3 and anti-CD28 Ab stimulation in vitro, the initial proliferative response and IL-2 secretion in CD28 Y189F transgenic T cells were severely compromised, while later responses were intact. In contrast to anti-CD3 and anti-CD28 Ab stimulation, PMA and anti-CD28 Ab stimulation failed to induce IL-2 production from CD28 Y189F transgenic T cells at any time point. Using the graft-vs-host reaction system, we assessed the role of the YMNM motif for CD28-mediated costimulation in vivo and found that CD28 Y189F transgenic spleen cells failed to engraft and could not induce acute graft-vs-host reaction. Together, these results suggest that the membrane-proximal tyrosine of CD28 is required for costimulation in vivo. Furthermore, these results indicate that the results from in vitro assays of CD28-mediated costimulation may not always correlate with T cell activation in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11238622     DOI: 10.4049/jimmunol.166.6.3797

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  24 in total

Review 1.  Activation and inhibition of lymphocytes by costimulation.

Authors:  Kenneth A Frauwirth; Craig B Thompson
Journal:  J Clin Invest       Date:  2002-02       Impact factor: 14.808

Review 2.  Genetic analysis of CD28 signaling.

Authors:  Tiffani A Greene; Virginia Smith Shapiro
Journal:  Immunol Res       Date:  2003       Impact factor: 2.829

Review 3.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

4.  In the absence of its cytosolic domain, the CD28 molecule still contributes to T cell activation.

Authors:  Stéphanie O Morin; Valentin Giroux; Cédric Favre; Yassina Bechah; Nathalie Auphan-Anezin; Romain Roncagalli; Jean-Louis Mège; Daniel Olive; Marie Malissen; Jacques A Nunès
Journal:  Cell Mol Life Sci       Date:  2015-03-01       Impact factor: 9.261

5.  Synthetic peptides containing ITIM-like sequences of IREM-1 (CD300F) differentially regulate MyD88 and TRIF-mediated TLR signalling through activation of SHP and/or PI3K.

Authors:  S-M Lee; K Suk; W-H Lee
Journal:  Clin Exp Immunol       Date:  2012-03       Impact factor: 4.330

6.  Regulated costimulation in the thymus is critical for T cell development: dysregulated CD28 costimulation can bypass the pre-TCR checkpoint.

Authors:  Joy A Williams; Karen S Hathcock; David Klug; Yohsuke Harada; Baishakhi Choudhury; James P Allison; Ryo Abe; Richard J Hodes
Journal:  J Immunol       Date:  2005-10-01       Impact factor: 5.422

7.  OX40 complexes with phosphoinositide 3-kinase and protein kinase B (PKB) to augment TCR-dependent PKB signaling.

Authors:  Takanori So; Heonsik Choi; Michael Croft
Journal:  J Immunol       Date:  2011-02-02       Impact factor: 5.422

8.  Induction of autoimmune disease in CTLA-4-/- mice depends on a specific CD28 motif that is required for in vivo costimulation.

Authors:  Xuguang Tai; Francois Van Laethem; Arlene H Sharpe; Alfred Singer
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-16       Impact factor: 11.205

9.  CD28 co-signaling in the adaptive immune response.

Authors:  Pavel Riha; Christopher E Rudd
Journal:  Self Nonself       Date:  2010-07-12

Review 10.  CD28 Costimulation: From Mechanism to Therapy.

Authors:  Jonathan H Esensten; Ynes A Helou; Gaurav Chopra; Arthur Weiss; Jeffrey A Bluestone
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.